Prognostic Value of 18FDG PET/CT Textural Indices in HNSCC
NCT03378193 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 284
Last updated 2018-07-23
Summary
Head and neck (HN) cancer is the sixth most common malignancy worldwide, with around 800,000 new cases and 320,000 deaths in 2015. These malignancies encompass cancers of the oral cavity, oropharynx, hypopharynx and larynx and concerned squamous cell carcinomas (SCC) 90% of the time.
Despite aggressive treatment strategies, the five-year survival rate has only marginally improved in the past decade especially because of a high rate (up to 40%) of loco-regional recurrence. Moreover, two-third of local relapse and lymph node metastases occur in the first 2 years after treatment. Hence, predicting tumor response to therapy remains a real challenge in head and neck cancers.
Usual prognostic factors include the tumor size, the lymph node involvement, the presence of distant metastasis, the anatomic subsite, and the human papilloma virus (HPV 16, 18) infection status. However, pre-treatment selection of patients with poor prognosis or who require intensified therapy remains difficult despite their careful evaluation.
HNSCC also present a high biologic heterogeneity with hypoxic area, necrotic regions, zones of high cellular proliferation and intra-tumoral angiogenic heterogeneity. A better characterization of tumor heterogeneity could help classify patients in different risk subgroups in order to improve their therapeutic management.
Pre-therapeutic 18F-fluorodeoxyglucose positron-emission tomography (FDG PET/CT) is recommended by guidelines to assess remote extension of locally advanced HNSCC and/or to look for synchronous cancer. Its prognostic significance has already been suggested and a selection of patients at risk of recurrence appears possible using different quantitative parameters. Indeed, static (SUV = Standardized Uptake Value), volumetric (MTV = Metabolic Tumor Volume, TLG = Total Lesion Glycolysis) and kinetic (RI = Retention Index) parameters were demonstrated to be independent prognostic factors in several studies.
Texture analysis is currently highly studied in order to characterize tumor heterogeneity, and consists in extracting texture indices from different imaging modalities such as FDG PET/CT. Calculating texture indices relies on choosing a contouring method to delineate a tumor volume of interest and selecting several parameters such as the resampling method, matrix definitions and indices formula. Several studies conducted on small series of patients with HNSCC have showed promising results to predict survival, analyzing various cancer anatomic subsites, tumor segmentation methods and texture indices.
The objective of this study is to assess the prognostic value of texture indices in a large cohort of patients with HSNCC, including any anatomic subtype and staging.
Conditions
- Cancer of Head and Neck
Sponsors & Collaborators
-
University Hospital, Brest
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-01-01
- Primary Completion
- 2018-03-30
- Completion
- 2018-03-30
Countries
- France
Study Locations
More Related Trials
-
Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET
NCT05889312 ·Status: RECRUITING
-
Performance of 18F-FDG Micro-PET-CT in the Assessment of Surgical Margins in Head and Neck Cancer
NCT07285564 ·Status: RECRUITING ·Phase: NA
-
Tumor Metabolism of Head and Neck Cancer in Patients Who Underwent Radiation Therapy Measured With F-18-FDG-PET
NCT00180245 ·Status: COMPLETED
-
Predictive Value of PET CT in the Histologic Lymph Node Status of Patients With Squamous Cell Carcinoma of the Oral N0 Clinical and Radiological Cavity.
NCT03947892 ·Status: UNKNOWN
-
Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy
NCT01663753 ·Status: COMPLETED ·Phase: NA
-
Pathological Validation of Functional Imaging in Head and Neck Squamous Cell Carcinoma
NCT01827709 ·Status: TERMINATED ·Phase: NA
-
A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients
NCT01506427 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
18F-FDG PET/CT Versus 18F-FDG PET/MRI in Detecting Locoregional Recurrence 3 Months After CRT in Head and Neck SCC
NCT04196985 ·Status: UNKNOWN ·Phase: NA
-
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
NCT00721799 ·Status: COMPLETED ·Phase: PHASE2
-
Combined FDG PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT01179360 ·Status: COMPLETED
-
[18F]HX4 PET/CT Imaging for Detection of Hypoxia
NCT02976883 ·Status: COMPLETED ·Phase: PHASE2
-
Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer
NCT00671437 ·Status: COMPLETED ·Phase: PHASE2
-
Validation of High-resolution PET/CT for the Pretherapeutic Lymphnode Staging of Head/Neck Cancer
NCT02372890 ·Status: COMPLETED
-
PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients
NCT03342378 ·Status: COMPLETED
-
Measurement of Head and Neck Tumor Hypoxia With PET-MRI
NCT05246475 ·Status: RECRUITING ·Phase: NA
-
The Diagnostic Value of PET/MRI in Head and Neck Cancer
NCT04117139 ·Status: UNKNOWN ·Phase: NA
-
Role of 18F-FDG PET/CT in Gastric Cancer
NCT05687552 ·Status: UNKNOWN
-
PET MRI as a Staging Tool for Head and Neck Cancer
NCT04750434 ·Status: COMPLETED
-
Role of PET Scan in the Evaluation of Early Response to Maintenance Treatment in Advanced Non-small-cell Lung Cancer
NCT02507518 ·Status: UNKNOWN ·Phase: PHASE2
-
Role of PET/MRI in Head and Neck Cancer
NCT04360993 ·Status: COMPLETED
-
Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma
NCT04031534 ·Status: COMPLETED ·Phase: PHASE2
-
Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
NCT06914999 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Prognostic Utility of the Imaging and Biological Signatures in Nasopharyngeal Carcinoma
NCT04417985 ·Status: COMPLETED ·Phase: NA
-
Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer
NCT01774760 ·Status: COMPLETED ·Phase: PHASE2
-
PET/CT: Role in Detecting Unknown Primary Head and Neck Cancer
NCT00656760 ·Status: COMPLETED ·Phase: NA